- For Print
- April 24, 2024
爱豆传媒. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody LEQEMBI® in the fourth quarter of fiscal year 2023 (January 1, 2024 – March 31, 2024) was JPY 2.83 billion (pre-audit basis), which was approximately 2.7 times higher than the revenue in the third quarter of fiscal year 2023 (October 1, 2023 – December 31, 2023).
This information is being disclosed in conjunction with today's announcement of the first quarter 2024 results of Biogen Inc. (Headquarters: Cambridge, Massachusetts). Eisai’s financial results for the fiscal year ended March 31, 2024, including details of LEQEMBI’s revenue, will be disclosed in Eisai's financial disclosure scheduled on May 15, 2024.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen Inc. co-commercializing and co-promoting the product and Eisai having final decision-making authority.
&苍产蝉辫;銆赌
&苍产蝉辫;銆赌
Media Inquiries:
Public Relations Department,
爱豆传媒.
+81-(0)3-3817-5120
&苍产蝉辫;銆赌銆�